Patents by Inventor Katharine Hilary Dixon

Katharine Hilary Dixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating ocular neovascularization
    Patent number: 9238057
    Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: January 19, 2016
    Assignee: Novartis AG
    Inventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
  • Method for Treating Ocular Neovascularization
    Publication number: 20130165503
    Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.
    Type: Application
    Filed: December 17, 2012
    Publication date: June 27, 2013
    Applicant: NOVARTIS AG
    Inventors: Romulus Kimbro BRAZZELL, Peter Anthony CAMPOCHIARO, Katharine Hilary DIXON, Michael KALEKO, Tianci LUO
  • Method for treating ocular neovascularization
    Patent number: 8338384
    Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.
    Type: Grant
    Filed: May 23, 2010
    Date of Patent: December 25, 2012
    Assignee: Novartis AG
    Inventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
  • Method for treating ocular neovascularization
    Publication number: 20100286253
    Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.
    Type: Application
    Filed: May 23, 2010
    Publication date: November 11, 2010
    Applicant: NOVARTIS AG
    Inventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
  • Method of treating ocular neovascularization
    Publication number: 20020183253
    Abstract: Methods are provided for the treatment of choroidal neovascularization by increasing, in an individual afflicted with choroidal neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to a choroidal neovascularization inhibiting effective amount, where the endostatin protein has anti-choroidal neovascularization activity in vivo.
    Type: Application
    Filed: February 21, 2002
    Publication date: December 5, 2002
    Inventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon